Upstream Processing

Improving mAb Manufacturing Productivity by Optimizing Buffer and Media Prep Process Flow

July 01, 2020

Innovative approaches, including ready-to-use materials and in-line dilution, can significantly streamline overall bioprocessing operations.

Plasma-Based Antibody Therapies Battle Against COVID-19

June 01, 2020

Therapies for early and late treatment and passive immunization of COVID-19 are needed and can be developed using antibodies from recovered patients.

Biopharmaceutical Manufacturing and the Power of Synthetic Biology

May 01, 2020

Synthetic biology has advanced the scope and scale with which biologically derived therapeutics can be developed.

Bioreactors Redefine Upstream Productivity

April 03, 2020

New bioreactor designs, coupled with better media, process intensification and analytics, continue to improve upstream bioprocessing.

Sartorius Launches New Automated Single-Use Bioproduction Platform

March 09, 2020

The new BIOSTAT STR Generation 3 with BIOBRAIN bioproduction platform offers process intensification with automated feed and bleed and integrated cell retention functionality.

Improving Upstream Predictability

March 02, 2020

Better understanding and control of cell behavior is yielding benefits, upstream and beyond.

The Future of Raw Material Sources for mAbs

March 02, 2020

The future of raw material sourcing for mAb production may lay in the sustainability of the source and the added benefits of newer technologies.

Maximizing the Effectiveness of Upstream Bioprocessing Through the Combination of Lab Informatics and Instrumentation

February 05, 2020

By establishing effective management of data and knowledge, it will be possible to employ advances, such as artificial intelligence and synthetic biology, to their full potential in upstream bioprocessing.

Cell Culture Variables for Gene Therapy Vectors

February 01, 2020

The production of viral vectors for use in gene therapy benefits from being able to use similar cell-culture processes as mAbs, but it faces limitations under current cell-culture technologies.

Horizon Discovery, Mammoth Biosciences Sign Collaboration and License Agreement

January 15, 2020

Horizon Discovery Group and Mammoth Biosciences have signed a collaboration and license agreement aimed at the development of the next generation of engineered Chinese hamster ovary (CHO) cell lines to improve biotherapeutics production.